Fungal Group Fungal Disease Source Guidelines Relevant Articles

Total Page:16

File Type:pdf, Size:1020Kb

Fungal Group Fungal Disease Source Guidelines Relevant Articles Fungal Fungal disease Source Guidelines Relevant articles Group ESCMID guideline for the diagnosis and management of Candida diseases 2012: 1. Developing European guidelines in clinical microbiology and infectious diseases 2. Diagnostic procedures 3. Non-neutropenic adult patients 4. Prevention and management of Candida diseases ESCMID invasive infections in neonates and children caused by Candida spp 5. Adults with haematological malignancies and after haematopoietic stem cell transplantation (HCT) 6. Patients with HIV infection or AIDS Candidaemia and IDSA clinical practice guidelines 2016 IDSA invasive candidiasis ISPD ISPD guidelines/recommendations Candida peritonitis Peritoneal Dialysis international article Invasive IDSA clinical practice guidelines 2010 IDSA WHO WHO management guidelines Guidelines for the prevention and Cryptococcal treatment of opportunistic infections in AIDSinfo meningitis HIV-infected Adults and adolescents Southern Guideline for the prevention, African diagnosis and management of HIV cryptococcal meningitis among HIV- clinicians infection persons: 2013 update society IDSA IDSA Clinical practice guidelines 2007 Histoplasmosis Guidelines for the prevention and treatment of opportunistic infections in disseminated AIDSinfo HIV-infected Adults and adolescents IDSA IDSA Clinical practice guidelines 2007 Histoplasmosis Guidelines for the prevention and treatment of opportunistic infections in acute pulmonary AIDSinfo HIV-infected Adults and adolescents Invasive IDSA IDSA Clinical practice guidelines 2008 aspergillosis ERS/EAACI guidelines for acute and Invasive ERS/EA chronic rhinosinusitis with and without rhinosinusitis ACI nasal polyps based on systematic review ESCMID and ECMM joint clinical guidelines for the diagnosis Mucormycosis ESCMID andmanagement of mucormycosis 2013 WHO guidelines for management of opportunistic infections and WHO antiretroviral treatment in adolescents and adults in ethopia Guidelines for the prevention and treatment of opportunistic infections in AIDSinfo Pneumocystis HIV-infected Adults and adolescents pneumonia Article: An official American Thoracic Society statement: Treatment of fungal infections in adult pulmonary and critical care patients. Talaromyces marneffei infection International ERS/ATS guidelines on ERS/ATS definition, evaluation and treatment of severe asthma Article: Allergic bronchopulmonary ABPA aspergillosis: review of literature and proposal of new diagnostic and classification critera Allergic Allergic fungal rhinosinusitis Occupational Lung Disease International ERS/ATS guidelines on SAFS ERS/ATS definition, evaluation and treatment of severe asthma Thunderstorm Asthma Chronic pulmonary ESCMID/ CPA guidelines in European aspergillosis (CPA) ERS Respiratory Journal 2015 Blastomycosis IDSA IDSA clinical practice guidelines 2008 IDSA Coccidioidomycosis guidelines IDSA 2005 Guidelines for the prevention and Coccidioidomycosis treatment of opportunistic infections in Chronic Lung AIDSinfo HIV-infected Adults and adolescents or Deep tissue Fungal keratitis Fungus ball of the IDSA Clinical practice guidelines 2008 IDSA sinus Granulomatous invasive fungal rhinosinusitis Histoplasmosis IDSA clinical practice guidelines 2007 chronic cavitary IDSA pulmonary Paracoccidioidomyc Guidelines in paracoccidioidomycosis osis (portugese) 2013 European guideline for the Candida balanitis management of balanoposthitis IDSA clinical practice guidelines 2016 LIFE Oesophageal Guidelines for Prevention and candidiasis Treatment of Opportunisitic infections AIDSinfo in HIV-infected Adults and adolescents IDSA IDSA clinical practice guidelines 2016 Mucosal infection Guidelines on the treatment of skin WHO and oral HIV-associated conditions in children and adults Oral candidiasis Guidelines for Prevention and Treatment of Opportunisitic infections AIDSinfo in HIV-infected Adults and adolescents Guideline: vuvovaginal candidosis (AWMF 015/072) (excluding chronic Vaginal thrush mucocutaneous candidosis) Athlete's foot Candida balanitis ESCMID and ECMM joint clinical guidelines for the diagnosis and Chromoblastomyco ESCMID management of systemic sis phaeohyphomycosis: diseases caused by black fungi Onychomycosis AAO- Clinical Practice Guidelines: Acute Otitis externa HNSF Otitis Externa 2014 Guidelines of care for superficial mycotic infections of the skin: Pityriasis versicolor AAD Pityriasis (tinea) versicolor Skin, nails and hair Ringworm Evidence-based Danish Guidelines Seborrheic for the treatment of Malassezia dermatitis related skin diseases Clinical practice guidelines for the Sporotrichosis management of sporotrichosis 2007 update Guidelines on the treatment of skin Tinea capitis WHO and oral HIV-associated conditions in children and adults Guidelines for the management of tinea capitis in children Guidelines on the treatment of skin WHO and oral HIV-associated conditions in children and adults Guidelines of care for superficial Tinea cruris mycotic infections of the skin: Tinea corporis, tinea cruris, tinea faciei, tinea manuum and tinea pedis Guidelines on the treatment of skin WHO and oral HIV-associated conditions in children and adults Guidelines of care for superficial Tinea manuum mycotic infections of the skin: Tinea corporis, tinea cruris, tinea faciei, tinea manuum and tinea pedis .
Recommended publications
  • Fungal Infections from Human and Animal Contact
    Journal of Patient-Centered Research and Reviews Volume 4 Issue 2 Article 4 4-25-2017 Fungal Infections From Human and Animal Contact Dennis J. Baumgardner Follow this and additional works at: https://aurora.org/jpcrr Part of the Bacterial Infections and Mycoses Commons, Infectious Disease Commons, and the Skin and Connective Tissue Diseases Commons Recommended Citation Baumgardner DJ. Fungal infections from human and animal contact. J Patient Cent Res Rev. 2017;4:78-89. doi: 10.17294/2330-0698.1418 Published quarterly by Midwest-based health system Advocate Aurora Health and indexed in PubMed Central, the Journal of Patient-Centered Research and Reviews (JPCRR) is an open access, peer-reviewed medical journal focused on disseminating scholarly works devoted to improving patient-centered care practices, health outcomes, and the patient experience. REVIEW Fungal Infections From Human and Animal Contact Dennis J. Baumgardner, MD Aurora University of Wisconsin Medical Group, Aurora Health Care, Milwaukee, WI; Department of Family Medicine and Community Health, University of Wisconsin School of Medicine and Public Health, Madison, WI; Center for Urban Population Health, Milwaukee, WI Abstract Fungal infections in humans resulting from human or animal contact are relatively uncommon, but they include a significant proportion of dermatophyte infections. Some of the most commonly encountered diseases of the integument are dermatomycoses. Human or animal contact may be the source of all types of tinea infections, occasional candidal infections, and some other types of superficial or deep fungal infections. This narrative review focuses on the epidemiology, clinical features, diagnosis and treatment of anthropophilic dermatophyte infections primarily found in North America.
    [Show full text]
  • Ringworm & Other Human Fungal Infections
    Ringworm & Other Human Fungal Infections McKenzie Pediatrics Ringworm, medically known as Tinea Corporis, is a common skin infection of childhood, and is not caused by a worm at all, but rather by a fungus. It is usually easily treated, and should not be seen as a source of social stigma. It is just one of many types of Tinea infections that affect humans. Tinea is a widespread group of fungal infections caused by dermatophytes. It is second to acne as the most frequently reported skin disease in the United States. Infection may occur through contact with infected humans (by way of shared combs, brushes, hats, pillows, clothing, or bedding) and animals (especially dogs and cats), soil, or inanimate objects. Tinea should be suspected in any red, scaly, itchy, and enlarging rash. Tinea is a superficial infection of the skin (Tinea Corporis), scalp (Tinea Capitis), nails (Tinea Unguium), groin (Tinea Cruris), hands (Tinea Manuum) or feet (Tinea Pedis). There are three types and 27 varieties of dermatophytes that cause human Tinea: Trichophyton, Epidermophyton, and Microsporum. Tinea Corporis (Ringworm) causes smooth and bare skin, typically surrounded by a raised, red, scaly “ring”. Lesions are often solitary, though may be multiple, and even overlapping. It is not nearly as common as what it is most often mistaken for: nummular eczema, a variety of eczema that causes round or oval scaly patches but without a clear area in the center. Nummular eczema tends to be more numerous, and is often less itchy than Ringworm. Topical treatments that are available over-the-counter usually work quite well for Tinea Corporis.
    [Show full text]
  • Diagnosis and Treatment of Tinea Versicolor Ronald Savin, MD New Haven, Connecticut
    ■ CLINICAL REVIEW Diagnosis and Treatment of Tinea Versicolor Ronald Savin, MD New Haven, Connecticut Tinea versicolor (pityriasis versicolor) is a common imidazole, has been used for years both orally and top­ superficial fungal infection of the stratum corneum. ically with great success, although it has not been Caused by the fungus Malassezia furfur, this chronical­ approved by the Food and Drug Administration for the ly recurring disease is most prevalent in the tropics but indication of tinea versicolor. Newer derivatives, such is also common in temperate climates. Treatments are as fluconazole and itraconazole, have recently been available and cure rates are high, although recurrences introduced. Side effects associated with these triazoles are common. Traditional topical agents such as seleni­ tend to be minor and low in incidence. Except for keto­ um sulfide are effective, but recurrence following treat­ conazole, oral antifungals carry a low risk of hepato- ment with these agents is likely and often rapid. toxicity. Currently, therapeutic interest is focused on synthetic Key Words: Tinea versicolor; pityriasis versicolor; anti­ “-azole” antifungal drugs, which interfere with the sterol fungal agents. metabolism of the infectious agent. Ketoconazole, an (J Fam Pract 1996; 43:127-132) ormal skin flora includes two morpho­ than formerly thought. In one study, children under logically discrete lipophilic yeasts: a age 14 represented nearly 5% of confirmed cases spherical form, Pityrosporum orbicu- of the disease.3 In many of these cases, the face lare, and an ovoid form, Pityrosporum was involved, a rare manifestation of the disease in ovale. Whether these are separate enti­ adults.1 The condition is most prevalent in tropical tiesN or different morphologic forms in the cell and semitropical areas, where up to 40% of some cycle of the same organism remains unclear.: In the populations are affected.
    [Show full text]
  • Review Article Sporotrichosis: an Overview and Therapeutic Options
    Hindawi Publishing Corporation Dermatology Research and Practice Volume 2014, Article ID 272376, 13 pages http://dx.doi.org/10.1155/2014/272376 Review Article Sporotrichosis: An Overview and Therapeutic Options Vikram K. Mahajan Department of Dermatology, Venereology & Leprosy, Dr. R. P. Govt. Medical College, Kangra, Tanda, Himachal Pradesh 176001, India Correspondence should be addressed to Vikram K. Mahajan; [email protected] Received 30 July 2014; Accepted 12 December 2014; Published 29 December 2014 Academic Editor: Craig G. Burkhart Copyright © 2014 Vikram K. Mahajan. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. Sporotrichosis is a chronic granulomatous mycotic infection caused by Sporothrix schenckii, a common saprophyte of soil, decaying wood, hay, and sphagnum moss, that is endemic in tropical/subtropical areas. The recent phylogenetic studies have delineated the geographic distribution of multiple distinct Sporothrix species causing sporotrichosis. It characteristically involves the skin and subcutaneous tissue following traumatic inoculation of the pathogen. After a variable incubation period, progressively enlarging papulo-nodule at the inoculation site develops that may ulcerate (fixed cutaneous sporotrichosis) or multiple nodules appear proximally along lymphatics (lymphocutaneous sporotrichosis). Osteoarticular sporotrichosis or primary pulmonary sporotrichosis are rare and occur from direct inoculation or inhalation of conidia, respectively. Disseminated cutaneous sporotrichosis or involvement of multiple visceral organs, particularly the central nervous system, occurs most commonly in persons with immunosuppression. Saturated solution of potassium iodide remains a first line treatment choice for uncomplicated cutaneous sporotrichosis in resource poor countries but itraconazole is currently used/recommended for the treatment of all forms of sporotrichosis.
    [Show full text]
  • (Sporanox Capsules) 280-A
    PRIOR AUTHORIZATION CRITERIA BRAND NAME (generic) SPORANOX ORAL CAPSULES (itraconazole) Status: CVS Caremark Criteria Type: Initial Prior Authorization Policy FDA-APPROVED INDICATIONS Sporanox (itraconazole) Capsules are indicated for the treatment of the following fungal infections in immunocompromised and non-immunocompromised patients: 1. Blastomycosis, pulmonary and extrapulmonary 2. Histoplasmosis, including chronic cavitary pulmonary disease and disseminated, non-meningeal histoplasmosis, and 3. Aspergillosis, pulmonary and extrapulmonary, in patients who are intolerant of or who are refractory to amphotericin B therapy. Specimens for fungal cultures and other relevant laboratory studies (wet mount, histopathology, serology) should be obtained before therapy to isolate and identify causative organisms. Therapy may be instituted before the results of the cultures and other laboratory studies are known; however, once these results become available, antiinfective therapy should be adjusted accordingly. Sporanox Capsules are also indicated for the treatment of the following fungal infections in non-immunocompromised patients: 1. Onychomycosis of the toenail, with or without fingernail involvement, due to dermatophytes (tinea unguium), and 2. Onychomycosis of the fingernail due to dermatophytes (tinea unguium). Prior to initiating treatment, appropriate nail specimens for laboratory testing (KOH preparation, fungal culture, or nail biopsy) should be obtained to confirm the diagnosis of onychomycosis. Compendial Uses Coccidioidomycosis2,3
    [Show full text]
  • Tinea Faciei Presenting Butterfly Erythema in a Boy
    TINEA FACIEI PRESENTING BUTTERFLY ERYTHEMA IN A BOY Serpil Şener Department of Dermatology, Beydagi State Hospital, Malatya, Turkey Tinea faciei is the most frequently misdiagnosed entity among cutaneous fungal infections. The atypical clinical features support the separation of this disease from tinea corporis. This often lacks a distinct raised scaly border, and may mimic a photodermatosis such as lupus erythematosus or dermatomyositis. Other photodermatoses to consider include polymorphous light eruption, contact dermatitis, and rosacea. In this article, a 9-year-old boy with tinea faciei presenting butterfly rash was reported because of its rarity. Key words: Dermatophytosis, tinea faciei, butterfly rash Eur J Gen Med 2007; 4(3):141-142 INTRODUCTION DISCUSSION Tinea faciei is a superficial dermatophyte Tinea faciei is a relatively uncommon infection limited to the glabrous skin of the superficial dermatophyte infection limited to face. In pediatric and female patients, the the glabrous skin of the face. It can be found infection may appear on any surface of the worldwide, but has a predilection for tropical face. In men, the condition is known as tinea humid climates (4). The causative agent varies barbae when a dermatophyte infection of according to the geographic region. In Asia, bearded areas occurs (1). The clinical features Trychophyton mentagrophytes and T. rubrum vary considerable. Annular or circinate are the most frequent etiologic agents (1,5). lesions, plaques with a raised margin, simple Infection results either from direct contact to papular lesions, and flat patches of erythema, an external source, for example a domestic as well as scaling, itching and exacerbation animal, or there may be secondary spread after sun exposure may occur (1-3).
    [Show full text]
  • Therapies for Common Cutaneous Fungal Infections
    MedicineToday 2014; 15(6): 35-47 PEER REVIEWED FEATURE 2 CPD POINTS Therapies for common cutaneous fungal infections KENG-EE THAI MB BS(Hons), BMedSci(Hons), FACD Key points A practical approach to the diagnosis and treatment of common fungal • Fungal infection should infections of the skin and hair is provided. Topical antifungal therapies always be in the differential are effective and usually used as first-line therapy, with oral antifungals diagnosis of any scaly rash. being saved for recalcitrant infections. Treatment should be for several • Topical antifungal agents are typically adequate treatment weeks at least. for simple tinea. • Oral antifungal therapy may inea and yeast infections are among the dermatophytoses (tinea) and yeast infections be required for extensive most common diagnoses found in general and their differential diagnoses and treatments disease, fungal folliculitis and practice and dermatology. Although are then discussed (Table). tinea involving the face, hair- antifungal therapies are effective in these bearing areas, palms and T infections, an accurate diagnosis is required to ANTIFUNGAL THERAPIES soles. avoid misuse of these or other topical agents. Topical antifungal preparations are the most • Tinea should be suspected if Furthermore, subsequent active prevention is commonly prescribed agents for dermatomy- there is unilateral hand just as important as the initial treatment of the coses, with systemic agents being used for dermatitis and rash on both fungal infection. complex, widespread tinea or when topical agents feet – ‘one hand and two feet’ This article provides a practical approach fail for tinea or yeast infections. The pharmacol- involvement. to antifungal therapy for common fungal infec- ogy of the systemic agents is discussed first here.
    [Show full text]
  • Tinea Faciei Presenting Butterfly Erythema in a Boy
    TINEA FACIEI PRESENTING BUTTERFLY ERYTHEMA IN A BOY Serpil Şener Department of Dermatology, Beydagi State Hospital, Malatya, Turkey Tinea faciei is the most frequently misdiagnosed entity among cutaneous fungal infections. The atypical clinical features support the separation of this disease from tinea corporis. This often lacks a distinct raised scaly border, and may mimic a photodermatosis such as lupus erythematosus or dermatomyositis. Other photodermatoses to consider include polymorphous light eruption, contact dermatitis, and rosacea. In this article, a 9-year-old boy with tinea faciei presenting butterfly rash was reported because of its rarity. Key words: Dermatophytosis, tinea faciei, butterfly rash Eur J Gen Med 2007; 4(3):141-142 INTRODUCTION DISCUSSION Tinea faciei is a superficial dermatophyte Tinea faciei is a relatively uncommon infection limited to the glabrous skin of the superficial dermatophyte infection limited to face. In pediatric and female patients, the the glabrous skin of the face. It can be found infection may appear on any surface of the worldwide, but has a predilection for tropical face. In men, the condition is known as tinea humid climates (4). The causative agent varies barbae when a dermatophyte infection of according to the geographic region. In Asia, bearded areas occurs (1). The clinical features Trychophyton mentagrophytes and T. rubrum vary considerable. Annular or circinate are the most frequent etiologic agents (1,5). lesions, plaques with a raised margin, simple Infection results either from direct contact to papular lesions, and flat patches of erythema, an external source, for example a domestic as well as scaling, itching and exacerbation animal, or there may be secondary spread after sun exposure may occur (1-3).
    [Show full text]
  • Therapies for Common Cutaneous Fungal Infections
    MedicineToday 2014; 15(6): 35-47 PEER REVIEWED FEATURE 2 CPD POINTS Therapies for common cutaneous fungal infections KENG-EE THAI MB BS(Hons), BMedSci(Hons), FACD Key points A practical approach to the diagnosis and treatment of common fungal • Fungal infection should infections of the skin and hair is provided. Topical antifungal therapies always be in the differential are effective and usually used as first-line therapy, with oral antifungals diagnosis of any scaly rash. being saved for recalcitrant infections. Treatment should be for several • Topical antifungal agents are typically adequate treatment weeks at least. for simple tinea. • Oral antifungal therapy may inea and yeast infections are among the dermatophytoses (tinea) and yeast infections be required for extensive most common diagnoses found in general and their differential diagnoses and treatments disease, fungal folliculitis and practice and dermatology. Although are then discussed (Table). tinea involving the face, hair- antifungal therapies are effective in these bearing areas, palms and T infections, an accurate diagnosis is required to ANTIFUNGAL THERAPIES soles. avoid misuse of these or other topical agents. Topical antifungal preparations are the most • Tinea should be suspected if Furthermore, subsequent active prevention is commonly prescribed agents for dermatomy- there is unilateral hand just as important as the initial treatment of the coses, with systemic agents being used for dermatitis and rash on both fungal infection. complex, widespread tinea or when topical agents feet – ‘one hand and two feet’ This article provides a practical approach fail for tinea or yeast infections. The pharmacol- involvement. to antifungal therapy for common fungal infec- ogy of the systemic agents is discussed first here.
    [Show full text]
  • Application to Add Itraconazole and Voriconazole to the Essential List of Medicines for Treatment of Fungal Diseases – Support Document
    Application to add itraconazole and voriconazole to the essential list of medicines for treatment of fungal diseases – Support document 1 | Page Contents Page number Summary 3 Centre details supporting the application 3 Information supporting the public health relevance and review of 4 benefits References 7 2 | Page 1. Summary statement of the proposal for inclusion, change or deletion As a growing trend of invasive fungal infections has been noticed worldwide, available few antifungal drugs requires to be used optimally. Invasive aspergillosis, systemic candidiasis, chronic pulmonary aspergillosis, fungal rhinosinusitis, allergic bronchopulmonary aspergillosis, phaeohyphomycosis, histoplasmosis, sporotrichosis, chromoblastomycosis, and relapsed cases of dermatophytosis are few important concern of southeast Asian regional area. Considering the high burden of fungal diseases in Asian countries and its associated high morbidity and mortality (often exceeding 50%), we support the application of including major antifungal drugs against filamentous fungi, itraconazole and voriconazole in the list of WHO Essential Medicines (both available in oral formulation). The inclusion of these oral effective antifungal drugs in the essential list of medicines (EML) would help in increased availability of these agents in this part of the world and better prompt management of patients thereby reducing mortality. The widespread availability of these drugs would also stimulate more research to facilitate the development of better combination therapies.
    [Show full text]
  • Fungal Infections (Mycoses): Dermatophytoses (Tinea, Ringworm)
    Editorial | Journal of Gandaki Medical College-Nepal Fungal Infections (Mycoses): Dermatophytoses (Tinea, Ringworm) Reddy KR Professor & Head Microbiology Department Gandaki Medical College & Teaching Hospital, Pokhara, Nepal Medical Mycology, a study of fungal epidemiology, ecology, pathogenesis, diagnosis, prevention and treatment in human beings, is a newly recognized discipline of biomedical sciences, advancing rapidly. Earlier, the fungi were believed to be mere contaminants, commensals or nonpathogenic agents but now these are commonly recognized as medically relevant organisms causing potentially fatal diseases. The discipline of medical mycology attained recognition as an independent medical speciality in the world sciences in 1910 when French dermatologist Journal of Raymond Jacques Adrien Sabouraud (1864 - 1936) published his seminal treatise Les Teignes. This monumental work was a comprehensive account of most of then GANDAKI known dermatophytes, which is still being referred by the mycologists. Thus he MEDICAL referred as the “Father of Medical Mycology”. COLLEGE- has laid down the foundation of the field of Medical Mycology. He has been aptly There are significant developments in treatment modalities of fungal infections NEPAL antifungal agent available. Nystatin was discovered in 1951 and subsequently and we have achieved new prospects. However, till 1950s there was no specific (J-GMC-N) amphotericin B was introduced in 1957 and was sanctioned for treatment of human beings. In the 1970s, the field was dominated by the azole derivatives. J-GMC-N | Volume 10 | Issue 01 developed to treat fungal infections. By the end of the 20th century, the fungi have Now this is the most active field of interest, where potential drugs are being January-June 2017 been reported to be developing drug resistance, especially among yeasts.
    [Show full text]
  • Sporothrix Schenckii and Sporotrichosis
    Anais da Academia Brasileira de Ciências (2006) 78(2): 293-308 (Annals of the Brazilian Academy of Sciences) ISSN 0001-3765 www.scielo.br/aabc Sporothrix schenckii and Sporotrichosis LEILA M. LOPES-BEZERRA1, ARMANDO SCHUBACH2 and ROSANE O. COSTA3 1Universidade do Estado do Rio de Janeiro/UERJ Instituto de Biologia Roberto Alcantara Gomes, Departamento de Biologia Celular e Genética Rua São Francisco Xavier, 524 PHLC, sl. 205, Maracanã 20550-013 Rio de Janeiro, RJ, Brasil 2Instituto Oswaldo Cruz, Instituto de Pesquisa Clínica Evandro Chagas Departamento de Doenças Infecciosas, Av. Brasil 4365, Manguinhos 21040-900 Rio de Janeiro, RJ, Brasil 3Universidade do Estado do Rio de Janeiro/UERJ, Hospital Universitário Pedro Ernesto Av. 28 de Setembro 77, Vila Isabel, 20551-900 Rio de Janeiro, RJ, Brasil Manuscript received on September 26, 2005; accepted for publication on October 10, 2006 presented by LUIZ R. TRAVASSOS ABSTRACT For a long time sporotrichosis has been regarded to have a low incidence in Brazil; however, recent studies demonstrate that not only the number of reported cases but also the incidence of more severe or atypical clinical forms of the disease are increasing. Recent data indicate that these more severe forms occur in about 10% of patients with confirmed diagnosis. The less frequent forms, mainly osteoarticular sporotrichosis, might be associated both with patient immunodepression and zoonotic transmission of the disease. The extracutaneous form and the atypical forms are a challenge to a newly developed serological test, introduced as an auxiliary tool for the diagnosis of unusual clinical forms of sporotrichosis. Key words: sporotrichosis, diagnosis, epidemiology, drugs, cell wall, antigens.
    [Show full text]